Hong Kong – September 07, 2026 -- Medtronic (NYSE: MDT) will invest approximately $700 million in Hong Kong-based Cornerstone Robotics as part of a strategic alliance granting the U.S. medtech giant distribution rights to the Sentire surgical robotic system in select markets outside the United States where the device is approved.
Medtronic gains distribution rights to Sentire outside the U.S.
The agreement covers markets where Sentire has already secured regulatory clearance, positioning the system alongside Medtronic's existing Hugo robotic surgical platform. Sentire received approval from China's National Medical Products Administration in 2024, followed by CE marking in the European Union and clearance from Singapore's Health Sciences Authority in May 2026 for general, gynecological, thoracic and urological minimally invasive procedures.
Cornerstone built vertical integration across hardware, software and imaging
Cornerstone Robotics developed its core hardware, control software, algorithms, and imaging and energy platforms internally, giving it direct control over product integration, quality and supply-chain resilience. The company operates three global R&D centers, six business centers, and a 30,000-square-meter manufacturing plant in China.
Executives frame deal as accelerating global robotic surgery access
"Our alliance with Medtronic positions us to accelerate and further expand our work,